Tag: psychedelics

Second California Senate Committee Approves Bill To Legalize Psychedelic Service Centers

A second California Senate committee has approved a bill to legalize psychedelic service centers where adults 21 and older could access psilocybin, MDMA, mescaline and DMT in a supervised environment with trained facilitators.

About a week after an initial panel cleared the legislation, the Senate Public Safety Committee passed the measure from Sen. Scott Wiener (D) in a 3-2 vote on Tuesday. It next heads to the Appropriations Committee.

The “Regulated Therapeutic Access to Psychedelics Act” has been drafted in a way that’s meant to be responsive to concerns voiced by Gov. Gavin Newsom (D) last year when he vetoed a broader proposal that included provisions to legalize low-level possession of substances such as psilocybin.

Instead, the new bill that’s now being unveiled would provide regulated access to psychedelics in a facilitated setting, without removing criminal penalties for possession outside of that context. It does not lay out any specific qualifying medical conditions that a person must have in order to access the services.

The measure had already undergone a series of mostly technical amendments before reaching committee. Wiener also agreed to revise the legislation at last week’s hearing to make it so psychedelics facilitators would need to have an existing professional health license, such as those for psychiatrists, social workers, drug and alcohol counselors and nurse practitioners.

Keep reading

Colorado Senate Passes Bill That Could Ban Social Media Users Who Post Positively About Drugs—Including Legal Psychedelics

Colorado’s Senate has approved a sweeping social media bill that, among other provisions, could force platforms to ban users for talking positively online about certain controlled substances, such as state-legal psychedelics, certain hemp products and even some over-the-counter cough syrups.

The legislation, SB24-158—a broad proposal concerning internet age verification and content policies—would require social media platforms to immediately remove any user “who promotes, sells, or advertises an illicit substance.”

Initially that provision would have applied to all controlled substances under state law—including state-legal marijuana—but an amendment last month from the bill’s sponsor, Sen. Chris Hansen (D), includes language saying that “a social media platform may allow a user to promote, sell, or advertise medical marijuana or retail marijuana to users who are at least twenty-one years of age” so long as the content complies with state cannabis laws.

The amended legislation would still apply to numerous other legal and illegal substances.

On Wednesday, the Senate voted 30–1 to pass the revised measure on third reading, with four members excused.

Earlier this week, the Senate Appropriations Committee also adopted two amendments to the bill, including one adding staff funding for the state attorney general’s office and another that could make the act subject to voter approval in November.

Critics say even with the marijuana-related amendment, the bill could create major problems for users trying to post benign—and legal—content around substances like cough medicine.

Keep reading

Researchers Ask Federal Court To Block DEA From Banning Two Psychedelics Under ‘Unconstitutional’ Administrative Process

Researchers are asking a federal court to block the Drug Enforcement Administration (DEA) from proceeding in its attempt to ban two psychedelics, arguing that the agency’s administrative approach to the proposed scheduling is unconstitutional.

Panacea Plant Sciences (PPS) filed a complaint and request for injunctive relief against DEA in the U.S. District Court for the Western District of Washington last week.

The legal challenge focuses on the agency’s recent scheduling of an administrative hearing to receive expert input on its controversial plans to classify 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) as Schedule I drugs under the Controlled Substances Act (CSA).

The filing doesn’t speak to the merits of the scheduling proposal—an issue that psychedelics researchers have previously addressed in public comment. Rather, PPS is contesting the administrative hearing process that’s preceding final rulemaking, arguing that DEA’s reliance on administrative law judges (ALJs) to settle such arbitration is unconstitutional based on U.S. Supreme Court precedent.

PPS said that because the Supreme Court has held that ALJs are considered “inferior officers,” current statutory removal protections unconstitutionally insulate them from executive control under Article II of the Constitution. That means DEA should not be permitted to subject researchers to an administrative hearing concerning the psychedelic scheduling proposal, the filing says.

“The hearing and scheduling poses a significant threat to the company,” it says. “PPS conducts research and development on medical technologies which include the use of DOI or DOC for development and as products themselves. Currently, DOI and DOC are not controlled.”

“Under the Controlled Substances Act (CSA) and its implementing regulations, PPS will be required to turn over to law enforcement or destroy our stock of DOI and DOC which means the rule-making acts as an effective taking of property,” the document says.

“As a result, when PPS received the hearing notice from DEA, it was faced with a stark choice: either default and lose automatically or defend itself against the DEA’s attempts to schedule DOI and DOC and its use of an ALJ-overseen adjudication,” it continues. “PPS is thus compelled to participate in the DEA’s adjudicatory proceedings.”

Keep reading

Congressional Lawmakers To Vote On GOP-Led Psychedelics Bill For Veterans This Week Despite VA Opposition

A congressional committee is set to vote this week on a GOP-led bill that would instruct the U.S. Department of Veterans Affairs (VA) to notify Congress if any psychedelics are added to its formulary of covered prescription drugs.

About a month after the House Veterans’ Affairs Health Subcommittee held an initial hearing on the legislation from Rep. Derrick Van Orden (R-WI), members will mark up the bill on Tuesday.

The panel had also discussed a measure from the subcommittee chair Rep. Mariannette Miller-Meeks (R-IA) during last month’s hearing, but that proposal isn’t on the Tuesday markup agenda—even though VA voiced support for it on the condition that certain amendments were made.

VA came out against the psychedelics bill that is getting a vote, arguing that it’s “unnecessary.”

The bill states that VA must report to Congress on the addition of any psychedelic medicines to its formulary within 180 days of their federal approval by Food and Drug Administration (FDA).

The report would need to include “the determination of the Secretary whether to include such drug in the formulary of the Department,” as well as “the justification of the Secretary for such determination,” the bill text says.

Currently, there are no psychedelic drugs that are federally approved to prescribe as medicine. But that could soon change, as FDA recently agreed to review a new drug application for MDMA-assisted therapy on an expedited basis. The agency has also designated psilocybin, and more recently an LSD-like compound, as “breakthrough therapies.”

Keep reading

DEA Agrees To Hold Hearing On Proposed Ban Of Two Psychedelics Amid Pushback From Researchers

The Drug Enforcement Administration (DEA) has scheduled an administrative hearing to get additional feedback from experts about its renewed push to ban two psychedelics after abandoning its original scheduling proposal in 2022.

More than a year after DEA announced its intent to classify 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) as Schedule I drugs under the Controlled Substances Act (CSA), the agency has agreed to hold a hearing before issuing a final rule.

DEA Administrator Anne Milgram signed off on the hearing notice on Thursday. It says that the agency’s administrative law judge will convene the meeting on June 10, at the request of three interested parties, including Panacea Plant Sciences, which had filed a motion contesting the proposed scheduling action last year.

Panacea Plant Sciences founder and CEO David Heldreth told Marijuana Moment on Monday that the company is “prepared to fight the DEA attempt to schedule DOI & DOC.”

“Beyond the scheduling attempt, we believe the DEA administrative law judges and system are unconstitutional,” he said, arguing that there’s legal precedent based on prior Supreme Court rulings. “We expect to file federal challenges to the ALJ prior to the hearing.”

In its notice about the psychedelics ban last year, DEA said its arguments about the merits of the scheduling action remained the same as in its prior abandoned ban attempt. It is maintaining that DOI and DOC hold high abuse potential with no established medical value. But it also notably described a change in the process to request an administrative hearing, which left some with the impression that the agency was deliberately complicating the procedure in the face of likely challenges from the psychedelics research community.

But, ultimately, DEA accepted the multiple requests for a hearing.

“Upon review of the requests for hearings, I have authorized a hearing, and direct the Chief Administrative Law Judge to assign the matter to an Administrative Law Judge who will complete all prehearing procedures, conduct a due process hearing…and issue a recommended decision for the Agency’s review and action,” Milgram said.

A DEA spokesperson told Marijuana Moment on Monday that they expect the notice to be posted on the online docket on Tuesday.

DEA backed down off its original proposed ban of the psychedelics following challenges from Panacea and researchers from Emory University. It remains to be seen how the agency will navigate the scheduling issue following the hearing with experts.

DEA separately withdrew from a proposal to ban five different tryptamine psychedelics in 2022 amid sizable pushback from the research and advocacy communities.

Keep reading

Why are so many young people taking hallucinogens?

From the microdosing boom to ketamine therapy, hallucinogens have experienced a boom in the last five years. During the COVID-19 lockdowns, research found that young people had been using psychedelics in place of drinking alcohol, with one in five experimenting with microdosing. It made sense that hallucinogens – which are often seen as ‘unsociable’ drugs – would have their moment in the sun at a time when pubs and clubs were closed and house parties resulted in £10,000 fines. But use of hallucinogens, which includes drugs such as LSD, magic mushrooms, 2C-B, DMT and ketamine, has only continued to increase since the pandemic, overtaking MDMA and ecstasy in the league table of most-used drugs. So what’s driving the trend?

It would be simple to suggest that the increase in hallucinogen use is a byproduct of young people staying at home. Research last year suggested that Gen Z was cutting back on clubbing in the face of the cost of living crisis, and one newspaper recently dubbed today’s youngsters “generation stay at home”. However, the majority of people who Dazed spoke to for this article say they use hallucinogens at raves, which suggests that it’s not that young people have stopped partying altogether, but instead that they’re partying differently.

For Becky, a 24-year-old student support worker living in Manchester, the switch from MDMA to 2C-B, a synthetic psychedelic drug which offers a mix of hallucinogenic and stimulant-like effects, was a no-brainer. “MDMA can make it hard to be around busy places, and actually makes me feel less sociable than 2C-B,” she tells Dazed. “But 2C-B makes music, lights and people more palatable and warmer.” She now uses 2C-B at every rave she goes to, which is about ten times a year. “I don’t do MDMA often at all now. I don’t enjoy it anymore, it just makes me anxious and stressed,” she adds.

Keep reading

Connecticut Lawmakers Approve Psilocybin Decriminalization Bill In Joint Committee Vote

Connecticut lawmakers have approved a bill to decriminalize psilocybin in a bicameral committee.

About two weeks after the legislature’s Joint Judiciary Committee first discussed the psychedelics proposal, members approved it on Tuesday.

The legislation would make possession of up to one-half an ounce of psilocybin punishable by a $150 fine, without the threat of jail time.

A second or subsequent violation would carry a fine of at least $200 but not more than $500. A person who pleads guilty or no contest on two separate occasions would be referred to a drug education program.

Police would be required to seize and destroy any amount of the psychedelic they find under the measure, HB 5297. Possession of more than a half-ounce of psilocybin would be considered a Class A misdemeanor.

Judiciary Committee Co-chair Rep. Steven Stafstrom (D) said the bill is partly about “recognizing that there has been quite a bit of study around this drug [and] recognizing the potential health benefits that veterans and others suffering from PTSD use it for and pushing in that direction.”

“Let’s be clear: This is not a legalization bill,” he said. “Possession of psilocybin under this bill would still be illegal. A police officer could still confiscate it could still destroy it and could issue an infraction ticket to someone in possession of small amounts of psilocybin.”

Keep reading

Utah Governor Lets Psychedelics Pilot Program Bill Become Law Without His Signature, Citing ‘Overwhelming Support’

The Republican governor of Utah has allowed a bill to become law without his signature that authorizes a pilot program for hospitals to administer psilocybin and MDMA as an alternative treatment option.

Gov. Spencer Cox (R) said in a letter to legislative leaders last week that he was letting the psychedelics legislation become enacted despite his reservations due to the “overwhelming support” it received, with both chambers unanimously approving the measure.

“I am generally supportive of scientific efforts to discover the benefits of new substances that can relieve suffering,” Cox said. “However, we have a task force that was set up specifically to advise the Legislature on the best ways to study Psilocybin and I’m disappointed that their input was ignored.”

The governor didn’t specify which specific task force recommendations he wanted to see incorporated, but the panel did advise against authorizing the regulated use of psychedelics before they’re approved by the federal Food and Drug Administration (FDA).

Lawmakers have cited the panel’s findings to support advancing the pilot program legislation from Senate Majority Whip Kirk Cullimore (R) and House Speaker Pro Tempore James Dunnigan (R).

The newly enacted measure provides for that regulated access at two types of health care systems in the state. Psychedelics can be administered by a privately owned, non-profit health care system with at least 15 licensed hospitals or within medical programs operated by institutions of higher education.

“A healthcare system may develop a behavioral health treatment program that includes a treatment” with psilocybin and MDMA that it “determines is supported by a broad collection of scientific and medical research,” the bill says.

By July 1, 2026, any hospital that establishes a psychedelics therapy pilot program will need to submit a report to the legislature that details which drugs are being utilized, healthcare outcomes of patients and any reported side effects.

The legislation Cox allowed to become enacted will take effect on May 1, 2024 and sunset after three years.

Keep reading

The wild psychedelic origins of indigenous mystical rites — as revealed by archaeology

We’ll never know when and where humans first discovered the mind-altering power of psychedelics. But it seems fair to state three things about our relationship with visionary drugs: it’s incalculably old, globally pervasive, and rich with meaning. Our ancestors likely began their long journey with naturally occurring psychotropic substances tens or even hundreds of thousands of years ago.

The nascent field of archaeochemistry has convincingly demonstrated Neanderthal use of psychoactive plants like yarrow and chamomile going back 50,000 years. Anthropologist Scott M. Fitzpatrick envisions the early hunter-gatherers of our own species encountering, consuming and experimenting “with a wide array of plants” and fungi — just like their Neanderthal cousins.

A generation ago, Terence McKenna famously introduced the Stoned Ape Theory, proposing an evolutionary advantage for a diet of psilocybin-containing mushrooms across the African savannas — not merely hundreds of thousands, but millions of years in our hominin past, prompting the development of proto-language, creativity, and religious insight well before the Neanderthals. Only now are scholars, like paleoanthropologist Lee Berger in South Africa, seriously investigating the bold claim.

Keep reading

Colorado Bill Would Force Social Media Platforms To Ban Users Who ‘Promote’ Marijuana, Psychedelics And Hemp Products

A center-right think tank is raising alarm about a Colorado bill that it says would make it illegal to talk positively about marijuana online. The prohibition would also apply to many hemp products as well as some federally legal pharmaceuticals.

Among other provisions, SB24-158—a broad proposal around internet age verification and content policies—would require social media platforms to immediately remove any user “who promotes, sells, or advertises an illicit substance.”

The bill’s definition of illicit substance includes not only illegal drugs but also many that are legal and regulated in Colorado. It pertains to any controlled substance under state law, including schedules I through V under state law.  That means the bill would affect state-legal marijuana, certain psychedelics—which voters legalized through a 2022 ballot measure—and even some over-the-counter cough syrups that contain small amounts of codeine.

Beyond scheduled drugs, the bill specifies that its restrictions also apply to certain hemp products with more than 1.25 milligrams THC or a CBD-to-THC ratio of less than 20 to 1 and most other hemp-containing products intended for human consumption.

If enacted onto law, companies would also need to publish “a statement that the use of the social media platform for the promotion, sale, or advertisement of any illicit substance…is prohibited.”

The R Street Institute says the restriction would impact not only cannabis companies but also any individual who posts positively about marijuana.

“Basically, the Colorado Legislature is trying to force social media companies to ban the promotion of marijuana,” the group’s social media director, Shoshanna Weissman, wrote in a new article. “And because what constitutes ‘promotion’ remains undefined, the bill would likely force platforms to remove all pro-marijuana free speech in a state where recreational use is legal.”

Not only is the ambiguity of “promotion” an issue, but the bill’s broad definition of illicit substances could also cause confusion, R Street says.

The think tank points out that the bill’s definition of illicit substances “would make it unlawful for businesses to promote them for sale or even for regular people to talk about their benefits online.”

“This clearly violates the First Amendment, as the bill is unconstitutionally narrow in scope,” Weissman wrote. “Basically, if speaking highly of or advertising these substances were truly dangerous, the state would have banned advertising in all its forms (e.g., print, television, digital).”

Keep reading